Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

ASCLERA

POLIDOCANOL

Standard Dose
10MG/2ML (5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview ASCLERA is listed in Drugs@FDA under application 021201 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient POLIDOCANOL Form and strength SOLUTION;INTRAVENOUS - 10MG/2ML (5MG/ML) Sponsor CHEMISCH FBRK KRSSLR Submission history Latest submission status date: 2025-01-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview ASCLERA is listed in Drugs@FDA under application 021201 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient POLIDOCANOL Form and strength SOLUTION;INTRAVENOUS - 10MG/2ML (5MG/ML) Sponsor CHEMISCH FBRK KRSSLR Submission history Latest submission status date: 2025-01-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.